The fourth dimension: Associations of change in albuminuria over time

Journal of the American Society of Nephrology

Volumn 22, Issue 7, 2011, Pages 1186-1188

  O'Seaghdha, Conall M ^a,b,c,d   Fox, Caroline S ^a,b,d  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ATENOLOL; LOSARTAN; RAMIPRIL; TELMISARTAN;

ALBUMINURIA; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DISEASE COURSE; EDITORIAL; GLYCEMIC CONTROL; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY FUNCTION; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); URINARY EXCRETION; URINE LEVEL;

EID: 79960142163     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2011050488     Document Type: Editorial

References (10)

1. Weir MR: Microalbuminuria and cardiovascular disease. Clin J Am Soc Nephrol 2: 581-590, 2007
2. Ninomiya T, Perkovic V, de Galan BE, Zoungas S, Pillai A, Jardine M, Patel A, Cass A, Neal B, Poulter N, Mogensen CE, Cooper M, Marre M, Williams B, Hamet P, Mancia G, Woodward M, Macmahon S, Chalmers J: Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 20: 1813-1821, 2009
3. Schmieder RE, Mann JFE, Schumacher H, Gao P, Mancia G, Weber MA, McQueen M, Koon T, Yusuf S, on behalf of the ONTARGET Investigators: Changes in Albuminuria Predict Mortality and Morbidity in Patients with Vascular Disease. J Am Soc Nephrol 22: 1353-1364, 2011
4. de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM: Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 110: 921-927, 2004 (Pubitemid 39128617)
5. Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlof B, Devereux RB, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wan Y: Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: Losartan intervention for endpoint reduction in hypertension study. Hypertension 45: 198-202, 2005 (Pubitemid 40179960)
6. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS: Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond. Stat Med 27: 157-172, discussion 207-212, 2008
7. Fox CS, Gona P, Larson MG, Selhub J, Tofler G, Hwang SJ, Meigs JB, Levy D, Wang TJ, Jacques PF, Benjamin EJ, Vasan RS: A multi-marker approach to predict incident CKD and microalbuminuria. J Am Soc Nephrol 21: 2143-2149, 2010
8. Suzuki K, Konta T, Takasaki S, Ikeda A, Ichikawa K, Sato H, Shibata Y, Watanabe T, Kato T, Kawata S, Kubota I: High variability of albuminuria in nondiabetic population: The Takahata Study. Clin Exp Nephrol 13: 452-459, 2009
9. Phillips AN, Smith GD: How independent are "independent" effects? Relative risk estimation when correlated exposures are measured imprecisely. J Clin Epidemiol 44: 1223-1231, 1991
10. Mertens TE: Estimating the effects of misclassification. Lancet 342: 418-421, 1993